Demographic and clinical parameters of patients
| Patients n = 30 | SE n = 14 | None SE n = 16 |
|---|---|---|
| Age in years | 23–50 (34.21 ± 8.89) | 22–65 (35.25 ±11.42) |
| Female | 6 (42.9%) | 9 (56.3%) |
| New-onset seizures age | 0.25-19 (6.71 ± 5.18) | 8-37 (15.19 ± 7.42) |
| Duration of the disease in years | 16-46 (27.43 ± 7.89) | 2-36 (20.06 ± 8.80) |
| Neuropsychiatric changes | 4 (30.8%) | 6 (37.5%) |
| Sleep seizures | 12 (87.5%) | 6 (37.5%) |
| Protein CSF Level > 50 mg/dl | 7 (50%) | 3 (18.8%) |
| CSF pleocytosis | 4 (28.6%) | 4 (25.0) |
| EEG findings | ||
| theta waves (> 5% EEG recording) | 9 (64.3%) | 3 (18.8%) |
| epileptiform discharges | 1 (7.1%) | 9 (56.3%) |
| MRI changes in the hippocampus | 1 (7.1%) | 3 (18.8%) |
| APE 2 score ≥ 4 | 7 (50%) | 5 (31.3%) |
Characteristics of patients with SE history vs those without SE history
| Student’s t-test | SE | N | Average | Standard deviation | t | p-value |
|---|---|---|---|---|---|---|
| Age | .00 | 16 | 35.25 | 11.416 | .274 | .786 |
| 1.00 | 14 | 34.21 | 8.894 | |||
| New-onset seizures | .00 | 16 | 15.1875 | 7.42266 | 3.575 | .001 |
| 1.00 | 14 | 6.7086 | 5.18461 | |||
| Duration of the disease | .00 | 16 | 20.06 | 8.797 | -2.399 | .023 |
| 1.00 | 14 | 27.43 | 7.891 | |||
| Chitotriosidase in serum (mmol/ml/h) | .00 | 14 | 46.429 | 33.5896 | .896 | .379 |
| 1.00 | 14 | 35.614 | 30.2185 | |||
| Chitotriosidase in CSF (mmol/ml/h) | .00 | 16 | 2.687500 | 1.8198443 | 2.240 | .033 |
| 1.00 | 14 | 1.440000 | 1.0807120 | |||
| APE 2 score | .00 | 16 | 3.00 | 1.155 | -.768 | .449 |
| 1.00 | 14 | 3.36 | 1.393 |